Levosimendan

左西孟旦

Report date: 2026/03/20 20:03:07
NME

Base Information

Drug NameLevosimendan
Drug Alias Name左西查坦Daxim左西咪旦Oral levosimendan - Orion左西孟坦 +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPotassium channel agonistsTroponin, cardiac muscle modulatorsVoltage-gated potassium channel agonists +[4] 
TargetsPotassium channelVoltage-gated potassium channelPhosphodiesterase 3 +[4] 
Therapy Area/IndicationsAcutely decompensated congestive heart failureVentricular Dysfunction, LeftST Elevation Myocardial Infarction +[18] 
Global Approved IndicationsHeart Failure
Approved Indications in ChinaHeart Failure
Original Approved Country/TerritorySweden
Original Approved Date2000/09/22
Country/TerritoryCzechiaBelgiumBulgaria +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesOrion Corp
China Registration ClassN/A

Develop Information

Active CompaniesPhyxius Pharma IncUniversitair Ziekenhuis BrusselTenax Therapeutics Inc +[8] 
Inactive CompaniesAbbott LaboratoriesUtah State UniversityLudwig Boltzmann Gesellschaft Gmbh +[11] 
Active IndicationsVentricular Dysfunction, LeftHeart FailureMyocarditis +[7] 
Inactive IndicationsAcutely decompensated congestive heart failureST Elevation Myocardial InfarctionCoronary Disease +[11] 

Other Information

ATC CodeC01CX08
Related LinksWikipediaDrugBankKEGG